Trial Profile
A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; TRC 102 (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 05 Oct 2023 Status changed from recruiting to completed.
- 06 Jun 2023 Results of GCOC cohort (n=9; enrolled as of 12/23/2022) assessing efficacy and safety of the combination TRC102 and TMZ in patients with granulosa cell ovarian cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2023 According to a TRACON Pharmaceuticals media release, company will present trial-in-progress posters in patients with granulosa cell ovarian cancer at the upcoming American Society of Clinical Oncology (ASCO) 2023 annual meeting, being held June 2-6, 2023.